Clinical Trials Browser

Phase 3 × Melanoma × 90 days × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT02821013 2026-03-10

STOP-GAP

Phase 3 Recruiting

Melanoma

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 1 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT05907122 2026-02-27

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Phase 3 Completed

Melanoma

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3 Recruiting

Melanoma, Nevus, Blue

NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Phase 3 Terminated

Melanoma

NCT06246916 2026-02-19

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Phase 3 Recruiting

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Phase 3 Active not recruiting

267 enrolled 8 charts

Melanoma

NCT07015190 2026-02-18

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Phase 3 Recruiting

Uveal Melanoma, Melanoma

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT06500455 2026-01-14

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Phase 3 Recruiting

BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06054555 2026-01-12

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma